Among the handful of drugmakers to advance a successful COVID-19 vaccine in 2020, Moderna—whose mRNA shot Spikevax was also ...

A complex molecular machine, the spliceosome, ensures that the genetic information from the genome, after being transcribed ...

In principle, mRNA vaccines are ideal for health emergencies as they can be quickly mass produced using a template. The problem is that current cell-based template production methods take too long, ...

Vaccine maker Moderna had no Valentine’s Day chocolates for investors when its financial results came out Friday. The company ...

Shares of Moderna, along with other vaccine makers, dropped further this year as lawmakers advanced President Donald Trump's ...

A complex molecular machine, the spliceosome, ensures that the genetic information from the genome, after being transcribed ...

Moderna (MRNA) shares move higher after reporting ... sales wane and the company had an unexpected charge for canceled manufacturing contract. Goldman Sachs US Biotechnology Analyst Salveen ...

A complex molecular machine, the spliceosome, ensures that the genetic information from the genome, after being transcribed into mRNA precursors, is correctly assembled into mature mRNA.

In a landmark achievement for both Uganda and the global medical community, the United States Patent and Trademark Office ...

While some of the initial zeal around localized vaccine production in Africa has waned since the height of the COVID-19 ...

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...